Karyopharm Therapeutics filed for Chapter 11 after reporting a $1.8 billion deficit as of Aug. 6 and naming Ayrmid as its lead bidder in a court-supervised sale. The biotech also secured $55 million in debtor-in-possession financing to stay operational while pursuing a restructuring deal expected to close in Q1 2027.

Why It Matters To Oncology

• Karyopharm markets Xpovio (selinexor), an oral XPO1 inhibitor approved in multiple myeloma and diffuse large B-cell lymphoma.

• The bankruptcy follows a major clinical setback: at the end of July, Xpovio failed as a maintenance-only therapy in a Phase III trial in certain patients with endometrial cancer.

• Karyopharm has also filed for FDA approval in myelofibrosis, leaving clinicians and drug developers watching closely for any impact on the review or future commercialization plans.

The Financials

• According to Karyopharm's second-quarter financial report, the company had a deficit of $1.8 billion as of Aug. 6.

• Karyopharm's stock fell more than 80% on the bankruptcy news Monday, after already losing more than 70% of its value following the endometrial cancer Phase III readout.

• The company lined up Ayrmid as lead bidder under a restructuring support agreement backed by lenders and stakeholders, though competing bids can still emerge during the court-supervised process.

• Existing lenders are providing $55 million in debtor-in-possession financing to support operations through the sale process.

What They're Saying

• CEO Richard Paulson said the proposed merger "provides a clear framework to pursue a value maximising transaction for our stakeholders while continuing our important work of advancing therapies for patients with multiple myeloma and myelofibrosis."

• The company did not provide a Monday update on its myelofibrosis FDA submission.

• Ayrmid's interest is notable after its prior effort to acquire bluebird bio last year fell short against competing bidders.

What's Next

• Ayrmid and Karyopharm plan to merge under the restructuring deal, subject to the Chapter 11 process and any higher competing offers.

• Karyopharm expects the transaction to close in the first quarter of 2027.

• For oncology stakeholders, key watch points are continuity of Xpovio supply, the status of the myelofibrosis filing, and whether selinexor development will be narrowed after the recent Phase III failure.

Reference: Karyopharm files for bankruptcy, plans to merge with Ayrmid